본문 바로가기

9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea

문서 유형
연구출판물 · 학술지 논문
등재
Nature IndexSCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
LANCET400(10362) · pp.1522 · 2022
피인용
Web of Science 61Scopus 67
FWCI (Scopus)
7.11
JCR IF
JCR 2021 202.731
ISSN
0140-6736

저자

  1. 목정하제1저자Pusan Natl Univ Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Busan, South Korea
  2. Lee, MyungsunInt TB Res Ctr, Div Clin Res, Seoul, South Korea
  3. Kim, Deog KyeomSeoul Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Seoul Metropolitan Govt,Boramae Med Ctr, Seoul, South Korea
  4. Kim, Ju SangCatholic Univ Korea, Coll Med, Dept Internal Med, Div Pulmonol & Crit Care Med,Incheon St Marys Hos, Seoul, South Korea
  5. Jhun, Byung WooSungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Pulm & Crit Care Med,Sch Med, Seoul, South Korea
  6. Jo, Kyung-WookUniv Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea
  7. 전두수Pusan Natl Univ, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea
  8. Lee, TaehoonUniv Ulsan, Ulsan Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Ulsan, South Korea
  9. Lee, Ji YeonNatl Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, Seoul, South Korea
  10. Park, Jae SeukDankook Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Cheonan, South Korea
  11. Lee, Seung HeonKorea Univ, Dept Pulmonol, Ansan Hosp, Ansan, South Korea
  12. Kang, Young AeYonsei Univ, Severance Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea
  13. Lee, Jung-KyuSeoul Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Seoul Metropolitan Govt,Boramae Med Ctr, Seoul, South Korea
  14. Kwak, NakwonSeoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seoul, South Korea
  15. Ahn, Joong HyunCatholic Univ Korea, Coll Med, Dept Internal Med, Div Pulmonol & Crit Care Med,Incheon St Marys Hos, Seoul, South Korea
  16. Shim, Tae SunUniv Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea
  17. Kim, Song YeeYonsei Univ, Severance Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Seoul, South Korea
  18. Kim, SeungmoKorean Inst TB, Dept Lab Med, Cheongju, South Korea
  19. Kim, KyungjongKorean Inst TB, Dept R&D, Cheongju, South Korea
  20. Seok, Kwang-HyukKorean Inst TB, Dept Lab Med, Cheongju, South Korea
  21. Yoon, SoyeongInt TB Res Ctr, Div Clin Res, Seoul, South Korea
  22. Kim, Young RanInt TB Res Ctr, Div Clin Res, Seoul, South Korea
  23. Kim, JisuSeoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul, South Korea
  24. Yim, DahaeSeoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul, South Korea
  25. Hahn, SeokyungSeoul Natl Univ, Dept Human Syst Med, Coll Med, Seoul, South Korea
  26. Cho, Sang NaeInt TB Res Ctr, Div Clin Res, Seoul, South Korea
  27. Yim, Jae-Joon교신저자Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea

초록

© 2022 Elsevier LtdBackground: With the introduction of new anti-tuberculosis drugs, all-oral regimens with shorter treatment durations for multidrug-resistant tuberculosis have been anticipated. We aimed to investigate whether a new all-oral regimen was non-inferior to the conventional regimen including second-line anti-tuberculosis drugs for 20–24 months in the treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis. Methods: In this multicentre, randomised, open-label phase 2/3 non-inferiority trial, we enrolled men and women aged 19–85 years with multidrug-resistant tuberculosis confirmed by phenotypic or genotypic drug susceptibility tests or rifampicin-resistant tuberculosis by genotypic tests at 12 participating hospitals throughout South Korea. Participants with fluoroquinolone-resistant multidrug-resistant tuberculosis were excluded. Participants were randomly assigned (1:1) to two groups using a block randomisation, stratified by the presence of diabetes and cavitation on baseline chest radiographs. The investigational group received delamanid, linezolid, levofloxacin, and pyrazinamide for 9 months, and the control group received a conventional 20–24-month regimen, according to the 2014 WHO guidelines. The primary outcome was the treatment success rate at 24 months after treatment initiation in the modified intention-to-treat population and the per-protocol population. Participants who were “cured” and “treatment completed” were defined as treatment success following the 2014 WHO guidelines. Non-inferiority was confirmed if the lower limit of a 97·5% one-sided CI of the difference between the groups was greater than −10%. Safety data were collected for 24 months in participants who received a predefined regimen at least once. This study is registered with ClinicalTrials.gov, NCT02619994. Findings: Between March 4, 2016, and Sept 14, 2019, 214 participants were enrolled, 168 (78·5%) of whom were included in the modified intention-to-treat population. At 24 months after treatment initiation, 60 (70·6%) of 85 participants in the control group had treatment success, as did 54 (75·0%) of 72 participants in the shorter-regimen group (between-group difference 4·4% [97·5% one-sided CI –9·5% to ∞]), satisfying the predefined non-inferiority margin. No difference in safety outcomes was identified between the control group and the shorter-regimen group. Interpretation: 9-month treatment with oral delamanid, linezolid, levofloxacin, and pyrazinamide could represent a new treatment option for participants with fluoroquinolone-sensitive multidrug-resistant tuberculosis. Funding: Korea Disease Control and Prevention Agency, South Korea

키워드

MOXIFLOXACINOUTCOMESBEDAQUILINE

식별자

Scopus EID
2-s2.0-85140470877
WoS UID
000923383000025